Skip to main content

Table 4 Details of the datasets and data processing methods used in the examined studies

From: Enhancing cancer differentiation with synthetic MRI examinations via generative models: a systematic review

Authors

Dataset

Patients

Anatomical area

Lesion

Modality

Pre-processing

Objective

Kitchen [78]

SPIE PROSTATEx

challenge 2016

-

Prostate

-

ADC, T2, \(K^{trans}\)

Normalization [0,1]

Synthesis

Hu [79]

Private

104

Prostate

Gleason Scores

(0 to 9)

Diffusion images

Rotation

Normalization

Flipping

Synthesis

Wang [81]

Private /

PROSTATEx

CS PCs: 134

non-CS PCa: 226

Prostate

CS & BPH

ADC

-

Classification

Yang [82]

Private /

PROSTATEx

CS PCs: 134

non-CS PCa: 226

Prostate

CS & BPH

ADC, T2w

Non-rigid registration

to ADC & T2w,

manually crop ROI

Classification

Wang [83]

TJPCa /

PROSTATEx

CS PCs: 134

non-CS PCa: 226

Prostate

CS & BPH

ADC, T2w

Crop & align

the ROI,

Resize pairs

Classification

Localization

F-Quilez [84]

PROMISE 12

80

Prostate

Whole gland

T2w

Linear interpolation

Outlier removal

Normalize [0,1]

CLAHE

Segmentation

Yu [85]

PROSTATEx’17

-

Prostate

Benign & malignant

T2w, ADC, DCE

Crop the ROI

Classification

Yan [88]

LocalPCa/

PROSTATEx

135/

CS PCa: 64

non-CS PCa: 124

Prostate

CS PCa

non-CS PCa

ADC

-

Privacy

Preservation &

Classification

Gao [89]

Private

96 pNET

Pancreas

Neuroendocrine

Tumors

T1ce

-

Classification

Gao [90]

Private

Train set: 398

Internal val set: 50

External val: 56

Pancreas

7 disease

Groups

T1ce

-

Classification

Haarburger [91]

Private

408

Breast

Benign

Malignant

Healthy

T1w, T1ce, T2w

Rescale intensities

Resample resolution

Crop to patches

Synthesize

Sun [92]

Liver100/

BRATS17

285/

100

Liver/

Brain

7 groups of lesions (23)/

HGG/LGG

T1w,T1ce,

T2w, & FLAIR

Normalize to zero mean

& unit variance

Crop

Segmentation

  1. ADC, Apparent Diffusion Coefficient; CS, Clinically Significant; PCa, Prostate Cancer; T2w, T2-weighted; DCE, Dynamic Contrast Enhanced; BPH, Benign Prostatic Hyperplasia; ROI, Region of Interest; pNET, pancreatic Neuroendocrine Tumor; T1ce, T1 contrast-enhanced; val, validation; LGG, Low-Grade Gliomas; HGG, High-Grade Gliomas; FLAIR, fluid-attenuated inversion recovery; Symbol ’-’ represents that the corresponding information was not provided in the publication